Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364695 | 0.82 | CHEK2 (0.46) | CHEK2AURKBSSTR2HRH3 | |
| SCHEMBL11447913 | 0.73 | LTA4H (0.50) | CHEK2LTA4H | |
| SCHEMBL14578215 | 0.73 | CHRNB4 (0.52) | CHEK2SSTR2LTA4H | |
| SCHEMBL6610218 | 0.73 | LTA4H (0.50) | CHEK2LTA4H | |
| SCHEMBL6608189 | 0.73 | LTA4H (0.49) | CHEK2AURKBLTA4H | |
| SCHEMBL11458469 | 0.72 | LTA4H (0.49) | CHEK2LTA4H | |
| Hydrochloric Acid SCHEMBL7323126 | 0.72 | LTA4H (0.48) | CHEK2AURKBLTA4H | |
| SCHEMBL11449210 | 0.72 | CHRNB4 (0.48) | LTA4H | |
| SCHEMBL6386675 | 0.71 | XDH (0.52) | HRH3 | |
| SCHEMBL11447854 | 0.71 | LTA4H (0.48) | CHEK2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1309569-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, WNK1 | CHEK2 1001/4885AURKB 951/4885SSTR2 1170/4885 |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | WNK2, CDK5, WNK1 | CHEK2 1052/4885AURKB 930/4885SSTR2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.